Group proceeding brought on behalf of those persons who purchased shares in the defendant (Mayne Pharma) in the period 24 November 2014 to 15 December 2016.
The claim alleges that Mayne breached its continuous disclosure obligations and engaged in misleading and deceptive conduct in relation to information it failed to provide to investors about an alleged price-fixing and market-share arrangement in the United States with executives of Heritage Pharmaceuticals, Inc, an American competitor to Mayne Pharma, which was the subject of a subpoena from the US Department of Justice, and later a subpoena and civil proceedings commenced by the Attorney General for the State of Connecticut.
The claim alleges that Mayne’s share price was inflated by its disclosure failures, and that shareholders suffered loss and damage as a result.
The deadline for opting out has now passed.
Please note the deadline for opting out has now passed.
If you are, or you think that you may be a group member, you should read the documents below carefully. The Notice (a copy of which is below) contains important information about your rights to (1) register your interest in the proceeding or (2) opt out of the proceeding.
In summary, if you fall within the definition of a group member:
• You must register your interest in accordance with the Notice by Wednesday, 4.00pm (AEST) on 28 June 2023 if you wish to obtain compensation by participating in any settlement reached between the plaintiff and defendant at the Court Ordered Mediation (or within 3 months after the first day of that mediation).
• You will remain a group member unless you take steps to opt out by Wednesday, 4.00pm (AEST) on 28 June 2023.
The definition of a “group member” is set out in the Notice.
Mayne Pharma's Defence filed on 17 December 2021 in the Mayne Pharma Group Proceeding (Class Action)
Statement of Claim filed on 8 October 2021 in the Mayne Pharma Group Proceeding (Class Action)
Funding Information Summary Statement filed on 21 August 2020 in the Mayne Pharma Group Proceeding (Class Action)
Group Proceeding Summary Statement filed on 21 August 2020 in the Mayne Pharma Group Proceeding (Class Action)